iCo to present phase 1 iCo-007 trial study April 23
Ticker Symbol: C:ICO
iCo to present phase 1 iCo-007 trial study April 23
iCo Therapeutics Inc (C:ICO)
Shares Issued 41,057,301
Last Close 4/16/2010
.49
Thursday April 22 2010 - News Release
Mr. John Meekison reports
ICO-007 FOR DIFFUSE DIABETIC MACULAR EDEMA TO BE PRESENTED AT RETINAL PHYSICIAN SYMPOSIUM 2010
iCo Therapeutics Inc.'s phase I clinical trial study employing iCo-007 in diffuse diabetic macular edema (DME) will be highlighted in a presentation at the Retinal Physician Symposium 2010. iCo expects to release final results of its Phase I study later in Q2 2010.
The presentation will be made by David S. Boyer, MD and is currently planned for 9:00 am EST on Friday, April 23, 2010 at the Atlantis Paradise Island Resort in the Bahamas and will feature prominent scientists, clinicians and healthcare experts in retina care presenting new therapies and treatment strategies for retinal diseases. Dr. Boyer will highlight previously disclosed data from the iCo-007 Phase I open label study.
Dr. Boyer is a practising ophthalmologist who specializes in the treatment of diseases of the retina and vitreous. He is a Senior Partner at the Retina-Vitreous Associates Medical Group and a Clinical Associate Professor at the University of Southern California. He also has an extensive research background involving trials for age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis. Dr. Boyer has been on the advisory boards for Alcon, Novartis, Eyetech/Pfizer, Genentech, Neurotech and the Macular Degeneration Partnership and is a reviewer for several ophthalmology and diabetes medical publications including Archives of Ophthalmology, American Journal of Ophthalmology, Diabetes Care, and Ophthalmology.
About iCo-007
Designed and discovered by ISIS Pharmaceuticals Inc. (NASDAQ: ISIS), iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the treatment of DME and diabetic retinopathy.
The primary endpoint of the Company's open label, dose escalating Phase I trial is safety, with visual acuity and measures of retinal thickness serving as secondary endpoints. Four U.S. clinical sites participated.
© 2010 Canjex Publishing Ltd.